Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.
Sarah Cheng, MD, PhD
Advertisement
Sarah Cheng, MD, PhD, is a clinical fellow in oculofacial plastic and orbital surgery at the University of California San Diego Shiley Eye Institute, where she studies the molecular biology of thyroid eye disease and how teprotumumab changes orbital tissue.
Articles by Sarah Cheng, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Duravyu misses wet AMD end point again as EyePoint pivots to DME
3
The Retina TL;DR with Dr. Weng: Thriving in fellowship with Amer Alsoudi, MD, and Monia Reding, MD
4
A vascular link: erectile dysfunction may signal glaucoma risk in men
5